<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157130</url>
  </required_header>
  <id_info>
    <org_study_id>NVCI 10-09</org_study_id>
    <nct_id>NCT01157130</nct_id>
  </id_info>
  <brief_title>Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory</brief_title>
  <official_title>Prescriptive Exercise Intervention During Active Treatment for Early Stage Breast Cancer Patients: A Breast Cancer Rehabilitation &amp; Exercise Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nevada Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nevada Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study compares the outcomes of a physical activity intervention begun at&#xD;
      diagnosis, continuing through active cancer treatment and into six months of survivorship&#xD;
      compared to the outcomes of a control group receiving limited information on activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients (with stage 0 to stage III breast cancer)receiving chemotherapy, radiation or both&#xD;
      chemotherapy and radiation will be included in the study.Randomization will be stratified by&#xD;
      disease stage at diagnosis, treatment modalities planned, and hormonal status. Each patient&#xD;
      will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be&#xD;
      achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight&#xD;
      machines and aerobic training using treadmills, elliptical trainers and stationary bicycles,&#xD;
      will be utilized in the intervention group. The control group will receive basic information&#xD;
      on physical activity but not be instructed. Any physical activity in this group will be&#xD;
      self-reported. Change in C-reactive protein will be the primary endpoint. Changes in other&#xD;
      laboratory values, DEXA measurements, and quality of life measurements will be secondary&#xD;
      endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in CRP</measure>
    <description>The primary endpoint for this study change in C-reactive protein.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory values</measure>
    <description>Compare changes in:&#xD;
Glucose&#xD;
Insulin&#xD;
Estradiol&#xD;
Testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition</measure>
    <description>Body composition parameters and bone density will be assessed using Dual Energy X-ray Absorptiometry (DEXA) and compared between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <description>Quality of Life will be measured and compared between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <description>Comparing overall survival and progression free survival between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Early Stage Breast Cancer (Stage 0-III)</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive basic information on physical activity but not be instructed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Regimen</intervention_name>
    <description>Exercise instruction</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consent to participate in study&#xD;
&#xD;
          2. Women aged 18 and older&#xD;
&#xD;
          3. Stage 0 to III breast cancer prior to any treatment and at time of diagnosis&#xD;
&#xD;
          4. Requires treatment that includes chemotherapy, radiation therapy or both chemotherapy&#xD;
             and radiation therapy&#xD;
&#xD;
          5. Adequate fitness to participate in a physical activity as assessed by the investigator&#xD;
&#xD;
          6. Willing and able to participate in a prescribed exercise program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic breast cancer (Stage IV)&#xD;
&#xD;
          2. Initiation of treatment regimen prior to enrollment&#xD;
&#xD;
          3. Treatment for breast cancer not requiring chemotherapy or radiation therapy&#xD;
&#xD;
          4. Patients who are pregnant (negative urine pregnancy test required at baseline to&#xD;
             determine eligibility in women of child bearing potential).&#xD;
&#xD;
          5. Currently lactating&#xD;
&#xD;
          6. Do not read, understand, or speak English&#xD;
&#xD;
        Eligible participants will not be included if they have:&#xD;
&#xD;
          1. known cardiac disease,&#xD;
&#xD;
          2. uncontrolled hypertension,&#xD;
&#xD;
          3. uncontrolled thyroid disease,&#xD;
&#xD;
          4. diabetes mellitus,&#xD;
&#xD;
          5. mental illness,&#xD;
&#xD;
          6. infection,&#xD;
&#xD;
          7. immune or endocrine abnormality,&#xD;
&#xD;
          8. body weight reduction I10% in past 6 months, and&#xD;
&#xD;
          9. positive exercise stress test.&#xD;
&#xD;
         10. Major surgery within last 6 months that requires exercise restriction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Milligan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nevada Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanne Eddington</last_name>
      <phone>702-821-0062</phone>
      <email>beddington@nvcancer.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Milligan, MD</last_name>
      <phone>702-822-5433</phone>
    </contact_backup>
    <investigator>
      <last_name>Karen Milligan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nevadacancerinstitute.org/</url>
    <description>Nevada Cancer Institute</description>
  </link>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Karen Milligan, MD</name_title>
    <organization>Nevada Cancer Institute</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Exercise</keyword>
  <keyword>CRP</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>BMI</keyword>
  <keyword>Nevada Cancer Institute</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Prescriptive exercise</keyword>
  <keyword>Physical Activity</keyword>
  <keyword>DEXA</keyword>
  <keyword>Obesity</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>Early Stage Breast Cancer Patients (stage 0-III)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

